1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine: reduces levels of cortical and hippocampal serotonin and norepinephrine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 130045 |
| CHEMBL ID | 537675 |
| CHEMBL ID | 1188920 |
| SCHEMBL ID | 4159466 |
| MeSH ID | M0213485 |
| Synonym |
|---|
| 2'-nh2-mptp |
| CHEMBL537675 , |
| 2-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)aniline |
| AKOS006276921 |
| CHEMBL1188920 |
| bdbm50374544 |
| 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine |
| 108114-93-8 |
| 2-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)benzeneamine |
| benzeneamine, 2-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)- |
| SCHEMBL4159466 |
| DTXSID00148416 |
| 2-amino-mptp |
| 2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)aniline |
| STARBLD0002585 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Unlike 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces consistent decreases in levels of striatal dopamine (DA) with considerably smaller and more variable effects on mouse brain levels of serotonin (5-HT) and norepinephrine (NE), a novel amine-substituted MPTP analogue, 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP), administered in a standard mouse dosing paradigm for MPTP (20 mg/kg x 4) did not affect striatal DA but led to marked reductions (60-70%) in levels of 5-HT, 5-hydroxyindoleacetic acid (5-HIAA), and NE measured in frontal cortex and hippocampus 1 week after treatment." | ( Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP): a comparative study with 2'-CH3-MPTP and MPTP. Andrews, AM; Murphy, DL, 1993) | 0.68 |
| " In the present report, we confirm and extend our original results to include dose-response data and the effect of selective uptake inhibition on the levels of monoamine neurotransmitters in various regions of the mouse brain following treatment with 2'-NH2-MPTP." | ( Fluoxetine and desipramine selectively attenuate 2'-NH2-MPTP-induced depletions in serotonin and norepinephrine. Andrews, AM; Murphy, DL, 1993) | 0.29 |
| " This dosing regimen causes substantial striatal dopamine depletion in mice." | ( 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine]. Andrews, AM; Mazzola-Pomietto, P; Murphy, DL; Unger, EL, 2002) | 0.67 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||